Ryan Scott

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages OncLive's social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: rscott@onclive.com

Articles

Fixed-Duration Ibrutinib/Venetoclax Elicits Meaningful Survival Benefit in High-Risk CLL/SLL

October 12th 2024

Fixed-duration ibrutinib plus venetoclax generated meaningful survival benefits and durable responses in high-risk subgroups of patients with CLL/SLL.

FDA Approves Single-Dose, Intravenous Paclitaxel Biosimilar for Breast Cancer

October 11th 2024

A single-dose formulation of paclitaxel for injectable suspension has been launched in the United States for metastatic breast cancer.

EU Green Lights CLDN18 RxDx Assay As Companion Diagnostic for Zolbetuximab in Gastric Cancer

October 11th 2024

CE certification was granted to the VENTANA CDLN18 RxDx assay for the assessment of CLDN18 protein expression in gastric or GEJ adenocarcinoma in Europe.

NMPA Grants Marketing Approval to NGS-Based Companion Diagnostic for Sunvozertinib in EGFR Exon 20+ NSCLC

October 11th 2024

A next generation sequencing–based companion diagnostic has received marketing approval in China for sunvozertinib in EGFR exon 20–positive NSCLC.

Shining a Light on the Importance of Prevention Strategies During Breast Cancer Awareness Month

October 10th 2024

Sunil Adige, MD, discusses how breast cancer awareness efforts can enable earlier detection, better disease management, and improved patient outcomes.

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes

October 9th 2024

Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer.

Emavusertib Plus Ibrutinib Is Under Investigation in the TakeAim Trial in PCNSL

October 7th 2024

Grzegorz S. Nowakowski, MD, discusses the methods and objectives of the part B expansion portion of the TakeAim Lymphoma study in patients with PCNSL.

Novel Anti-Estrogen Therapies Are Poised to Expand Treatment Options in Advanced ER+ Breast Cancer

October 4th 2024

Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.

Emavusertib-Focused Research Is Poised to Expand the PCNSL Treatment Paradigm

October 4th 2024

Grzegorz S. Nowakowski, MD, discusses the unique mechanism of action of emavusertib and highlights the phase 1/2 TakeAim Lymphoma trial in PCNSL.

Real-World Analysis Shows High, Durable Transfusion Independence Rates With Luspatercept in Lower-Risk MDS

October 3rd 2024

Luspatercept generated high rates of durable transfusion independence for patients with lower-risk myelodysplastic syndrome in a real-world analysis.

Uncovering and Addressing Unmet Needs in Pediatric Cancer Care

October 2nd 2024

Saro H. Armenian, DO, MPH, discusses ongoing research that aims to enhance the quality of care for childhood cancer survivors.

De-Escalated Neoadjuvant Treatment Does Not Compromise Survival Outcomes in HR+/HER2+ Early Breast Cancer

October 2nd 2024

Oleg Gluz, MD, highlights the feasibility of de-escalated neoadjuvant therapy plus trastuzumab and pertuzumab in patients with HR+/HER2+ breast cancer.

Sonrotoclax/Dexamethasone Combo Is Tolerable, Generates Deep Responses in t(11:14)+ R/R Myeloma

September 30th 2024

Sonrotoclax plus dexamethasone was well tolerated and produced early, durable responses in patients with myeloma harboring t(11:14).

Prostate Cancer Awareness Efforts Target Patient Education, Treatment Access, and Survivorship Care

September 30th 2024

Bertram Yuh, MD, discusses the value of genetic testing, long-term disease management, and raising awareness during Prostate Cancer Awareness Month.

P-BCMA-ALLO1 May Be Safe, Rapid, and Active Allogeneic CAR T-Cell Therapy in Pretreated R/R Myeloma

September 30th 2024

Treatment with P-BCMA-ALLO1 demonstrated clinical activity and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.

First-Line Cadonilimab Plus Chemo Wins Approval in China for Advanced Gastric/GEJ Adenocarcinoma

September 30th 2024

Cadonilimab plus chemotherapy has been approved in China for first-line locally advanced or metastatic gastric/GEJ adenocarcinoma.

Childhood Cancer Awareness Month Shines a Light on Treatment Interventions and Advancements

September 28th 2024

Saro H. Armenian, DO, MPH, raises awareness for childhood-related cancer interventions during Childhood Cancer Awareness Month.

Breast Cancer Experts Spotlight Early-Phase and Real-World Research at the 2024 ESMO Congress

September 26th 2024

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

Preliminary Data Demonstrate High CR Rate With Detalimogene in BCG-Unresponsive NMIBC With CIS

September 26th 2024

Detalimogene voraplasmid generated a 71% complete response rate in patients with BCG-unresponsive non–muscle invasive bladder cancer and CIS.

sNDA for Darolutamide Plus ADT in mHSPC Submitted for FDA Review

September 26th 2024

A supplemental new drug application seeking to expand the indication for darolutamide plus ADT in mHSPC has been submitted to the FDA.

NEXT PAGE
PREVIOUS PAGE